Jacobs Journal of Bone Marrow and Stem Cell Research
Pomalidomide as Consolidation Therapy after Salvage Autologous Stem Cell Transplant
Published on: 2018-09-10
Recent advancements in the treatment multiple myeloma (MM) have improved patient outcomes in both the first-line as well as the relapsed/refractory settings. High-dose chemotherapy plus autologous stem cell transplant followed by maintenance therapy remains the standard of care as a front-line treatment for eligible patients. Unfortunately, most patients still evidence minimal residual disease after their initial transplant and almost all patients eventually relapse. In the setting of relapsed MM, salvage autologous stem cell transplant should be considered in patients who showed a good and durable response to their initial transplant. However, it is currently unknown whether patients will receive a similar benefit from maintenance therapy after salvage autologous transplant, as they do in the first-line setting. Here we describe the clinical course of four patients who received consolidation/maintenance treatment with pomalidomide after salvage therapy with high-dose melphalan plus autologous stem cell rescue and in whom this combination resulted in excellent clinical outcomes.